AllAnalyst Report
logoMorningstarOctober 19, 2020

AbbVie Inc.: President Trump’s Updated Healthcare Policy Targets Drug Costs, but Implementation Looks Tough

Symbols
ABBV
Sector(s)
Healthcare
Rating
Premium
Current Price
$104.89
Fair Value
Premium
Economic Moat
Premium
Stewardship
Premium
Summary

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013. The recent announced acquisition of Allergan will add several new drugs in aesthetics and women's health.

Premium
Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE